CID 11966249

Base Information

• Chemical Name: CID 11966249
• CAS No.: 11114-20-8
• Molecular Formula: Unspecified
• Molecular Weight: 788.65764
• Hs Code.: 13023990
• European Community (EC) Number: 234-350-2
• Mol file: 11114-20-8.mol

Synonyms:11114-20-8;[(2R,3S,4R,5R,6S)-6-[[(1R,3S,4R,5R,8S)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1R,3R,4R,5R,8S)-8-[(2S,3R,4R,5R,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-(hydroxymethyl)oxan-3-yl] sulfate;YC30039

Chemical Property of CID 11966249

Chemical Property:

• Appearance/Colour: White/yellowish powder
• PSA: 394.53000
• LogP: -6.52700
• Solubility.: H2O: 5 mg/mL hot, soluble
• Water Solubility.: H2O: 5 mg/mL hot, soluble
• XLogP3: -8.5
• Hydrogen Bond Donor Count: 8
• Hydrogen Bond Acceptor Count: 25
• Rotatable Bond Count: 10
• Exact Mass: 788.09870898
• Heavy Atom Count: 51
• Complexity: 1380

Purity/Quality:

99% ^*data from raw suppliers

k-Carrageenan ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: C1C2C(C(O1)C(C(O2)O)O)OC3C(C(C(C(O3)CO)OS(=O)(=O)[O-])OC4C(C5C(C(O4)CO5)OC6C(C(C(C(O6)CO)OS(=O)(=O)[O-])O)O)O)O
• Isomeric SMILES: C1[C@@H]2[C@@H]([C@H](O1)[C@H]([C@H](O2)O)O)O[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)OS(=O)(=O)[O-])O[C@@H]4[C@@H]([C@@H]5[C@H]([C@H](O4)CO5)O[C@H]6[C@@H]([C@H]([C@H]([C@H](O6)CO)OS(=O)(=O)[O-])O)O)O)O
• Uses: κ-?Carrageenan is a sulfated linear polysaccharide of D-?galactose and 3,?6-?anhydro-?D-?galactose extracted from certain red seaweeds of the Rhodophyceae class. κ-?Carrageenan is used in the food industry as thickening, gelling and protein-?suspending agents, and by the pharmaceutical industry in pills and tablets. The carrageenans are sulphate gums found in members of the Rhodophyceae. They consist of mixtures of polysaccharides which are mainly composed of D-galactose units linked 1~3 and 1~4. A high proportion ofthe units are substituted with sulphate half-ester groups. The carrageenans are useful stabilisers in foods.

Refernces

Dihydropyridine C-glycoconjugates by organocatalytic Hantzsch cyclocondensation. Stereoselective synthesis of α-threofuranose C-nucleoside enantiomers

10.1039/b900422j

The research explores the synthesis of dihydropyridine C-glycoconjugates using an organocatalytic Hantzsch cyclocondensation approach. The primary purpose of this study is to develop a mild and stereoselective method for synthesizing biologically relevant C-nucleosides, which are known for their potential pharmacological properties. The researchers utilized L-proline as an organocatalyst to facilitate the cyclocondensation of C-glycosyl aldehydes with ?-ketoesters and enamino esters, resulting in the formation of dihydropyridine C-glycoconjugates. Key chemicals involved include C-glycosyl aldehydes derived from red seaweed polysaccharides, such as agarose and kappa-carrageenan, which serve as the carbohydrate building blocks. Kappa-carrageenan, along with agarose, is a red seaweed polysaccharide that the researchers utilized to prepare the C-glycosyl aldehydes necessary for the Hantzsch cyclocondensation reactions. These C-glycosyl aldehydes, such as 3,6-anhydro-L-galactose aldehyde, are crucial for the formation of the dihydropyridine C-glycoconjugates. The presence of the sulfate group and threofuranosyl moiety in these carbohydrate derivatives is highlighted as being particularly relevant for the study's aim of identifying bioactive dihydropyridine glycoconjugates. The study concludes that the use of L-proline as a catalyst not only enhances the yield of the desired products but also ensures high stereoselectivity (de >95%), allowing for the preparation of both enantiomers of a-threofuranose C-nucleosides. This method represents a significant improvement over previous procedures, offering a more efficient and selective route for the synthesis of these compounds, which could have implications for the development of new drug candidates.